DiagnosTear Technologies Inc.
DTR.CD operates in the Advanced Medical Equipment & Technology industry, providing specialized medical devices and technologies to healthcare providers and patients.
Business. DTR.CD operates in the Advanced Medical Equipment & Technology industry within the broader Healthcare Services & Equipment sector. The company generates revenue primarily through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DTR.CD operates in the Advanced Medical Equipment & Technology industry within the broader Healthcare Services & Equipment sector. The company generates revenue primarily through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
DTR.CD's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 5.69, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's operating cash flow is negative at -2,217,000 CAD, and its free cash flow is also negative at -3,225,000 CAD, indicating a lack of cash generation from operations.
Profitability metrics show that DTR.CD is currently unprofitable, with a return on equity of -1.334 and a return on assets of -1.0033. These figures are below the industry median for the Advanced Medical Equipment & Technology sector, which typically sees positive returns on equity and assets. The company's operating income and net income are both negative, at -3,566,000 CAD and -3,319,000 CAD, respectively.
DTR.CD's revenue concentration is not disclosed in the available data, but the company's operations are primarily focused on the Advanced Medical Equipment & Technology industry. There is no indication of significant geographic diversification in the provided financial data.
The company's growth trajectory is uncertain, as there is no capital expenditure reported in the latest financial data, and the outlook for the current fiscal year does not include specific revenue growth projections. The absence of capital investment may limit the company's ability to scale operations or develop new products in the near term.
Risk factors for DTR.CD include its negative net cash position after subtracting total debt, which could impact its ability to fund operations or respond to market changes. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding data. However, the lack of positive cash flow and profitability raises concerns about long-term sustainability.
Recent events related to DTR.CD are not detailed in the available data, but the company's financial performance suggests a need for strategic adjustments to improve profitability and cash flow.
- DTR.CD has a conservative capital structure with a low debt-to-equity ratio of 0.07.
- The company is currently unprofitable, with a return on equity of -1.334 and a return on assets of -1.0033.
- DTR.CD's liquidity is medium, with a current ratio of 5.69, but it has negative operating and free cash flows.
- The company's growth trajectory is uncertain, with no capital expenditure reported in the latest financial data.
- DTR.CD faces risk from its negative net cash position after subtracting total debt.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- DTR.CD Market data — financials · 2026-05-27